AveXis (AVXS) Tops Q2 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
AveXis Reports Second Quarter 2016 Financial and Operating Results and Interim Data from Ongoing Phase 1 Trial of AVXS-101 in Spinal Muscular Atrophy Type 1
August 11, 2016 4:01 PM EDT-- Interim data through July 1 showed no events --
-- Continued motor function improvement with 25% of patients in the proposed therapeutic dose group in the normal range --
-- FDA requested Type B Meeting to discuss SMA Type 1 clinical development pathway --
-- Conference call and webcast August 11 at 4:30 p.m. EDT --
CHICAGO, Aug. 11, 2016 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ: AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic... More
